This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Tariquidar

Celtic Pharmaceutical Holdings L.P.

Drug Names(s): XR9576

Description: Tariquidar is a potent small-molecule inhibitor of the P-glycoprotein pump, designed to treat multi-drug resistance (MDR) in cancer.

Deal Structure: In September 2005, Celtic Pharmaceutical completed its takeover of Xenova Group plc and took full ownership of its drug candidate portfolio.

Xenova Group plc signed an exclusive licence agreement with QLT Inc in August 2001 for the development and for the marketing in the United States, Canada and Mexico of Xenova's multi-drug resistance (MDR) modulator, XR9576, for the treatment of MDR in cancer.

QLT returned the rights to Tariquidar back to Xenova in 2005.


Tariquidar News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug